EIGR - Eiger Biopharmaceuticals - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Eiger Biopharmaceuticals's activity chart (see below) currently has 23 price targets and 18 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 38.1% with an average time for these price targets to be met of 427.21 days.

Most recent stock forecast was given by from CITI on 29-Aug-2023.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Yigal Nochomovitz (CITI)

Buy Since 26-Jun-2019

$26

Please subscribe to see extended stock data

Brian Skorney (BAIRD)

Buy

$0.95 (46.34%)

Please subscribe to see extended stock data

Madhu Kumar (GOLDMAN SACHS)

Buy Since 09-May-2018

$150

$147.95 (7217.07%)

Please subscribe to see extended stock data

Robert Hazlett (BTIG)

Buy Since 19-Dec-2018

$44

Please subscribe to see extended stock data

Michael Higgins (LADENBURG)

Buy Since 16-May-2018

$29

$26.95 (1314.63%)

$690

Please subscribe to see extended stock data

Show more analysts

Load Price Targets and Ratings Chart

Please expand the browser size to see the chart

What is EIGR (Eiger Biopharmaceuticals) average time for price targets to be met?

On average it took 427.21 days on average for the stock forecasts to be realized with a an average price target met ratio 38.1

Which analyst has the current highest performing score on EIGR (Eiger Biopharmaceuticals) with a proven track record?

LIANA MOUSSATOS

Which analyst has the most public recommendations on EIGR (Eiger Biopharmaceuticals)?

Liana Moussatos has 19 price targets and 15 ratings on EIGR

Which analyst is the currently most bullish on EIGR (Eiger Biopharmaceuticals)?

Edward Tenthoff with highest potential upside - $717.95

Which analyst is the currently most reserved on EIGR (Eiger Biopharmaceuticals)?

Yigal Nochomovitz with lowest potential downside - -$0

EIGR - Eiger Biopharmaceuticals - Stock Forecast

Stock Analyst Price Targets - Review

Best performing analysts who are covering EIGR - Eiger Biopharmaceuticals:

Please expand the browser size to see the chart